PTN 250117 7.50C (PTN250117C7500) Stock Options, News & Quotes

English
中文繁體
中文简体

Download

Mobile

Moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US OptionsDetailed Quotes

PTN250117C7500

Watchlist

0.10
0.000.00%

15min DelayClose Jan 2 16:00 ET

0.00High0.00Low

Intraday

5D
Daily

News

Palatin Technologies: Positive Phase 2b Results and Strategic Growth Opportunities Justify Buy Rating
TipRanksDec 20, 2024 12:45 ET · Ratings
Express News | Palatin Technologies Inc - Bremelanotide Well Tolerated With No Serious Adverse Events
ReutersDec 19, 2024 07:30 ET
Express News | Palatin Announces Positive Phase Iib Breakout Study Results in Patients With Type 2 Diabetic Nephropathy
ReutersDec 19, 2024 07:30 ET
Palatin Announces Positive Phase IIb BREAKOUT Study Results in Patients With Type 2 Diabetic Nephropathy
PR NewswireDec 19, 2024 07:30 ET
Palatin Announces Exercise of Warrants for Approximately $3.4 Million Gross Proceeds
PR NewswireDec 16, 2024 07:30 ET
Express News | HC Wainwright & Co. Reiterates Buy on Palatin Techs, Maintains $17 Price Target
BenzingaNov 25, 2024 11:25 ET

Comments

APIP

Dec 30, 2024 02:49

So many investment opportunities are worth noting! Click to view the 2025 investment outlook>>

2025 ahead: New dreams, new paths

Jaguar8

Dec 19, 2024 17:46

🟢 Watchlist FRIDAY December 20,2024. N F A !

NOTE!
1. NFA
2. Do not open position without chart confirmation, indicators, momentum.
3. Check current shorts availability on FINTEL.io
4. Scale out and secure profits
5. Always remember shorts include dark pools.
6. Most importantly, don’t blame for your losses. I already give watchlist and stock education. The ball is on you.
7. I DO NOT give buy or sell advice
8. COH (cash on hand); AH (after hours): RTH (regular trading hours)
$Aadi Biosciences (AADI.US)$ PR AH 12/...

Jaguar8

Dec 19, 2024 06:32

NEWS

$Palatin Technologies (PTN.US)$
Palatin Announces Positive Phase IIb BREAKOUT Study Results in Patients with Type 2 Diabetic Nephropathy
Thursday, 19th December at 7:30 am
• Open label study designed to evaluate the safety, tolerability, and efficacy of bremelanotide in patients with Type 2 diabetic nephropathy
• Demonstrated efficacy at 6 months
◦ 71% percent of patients achieved a >30% reduction in the urine protein to creatinine ratio (UP/Cr)
◦ 71% of patients achieved improved or stab...

Trytosaveabit

Dec 19, 2024 06:30

News

$Palatin Technologies (PTN.US)$ Reuters· just
Palatin Announces Positive Phase Iib Breakout Study Results in Patients With Type 2 Diabetic Nephropathy! Palatin Technologies Inc - Bremelanotide Well Tolerated With No Serious Adverse Events

The Flow

Nov 14, 2024 12:58

I am feeling it!!!

Share Your Profit/Loss